Loading
A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Shanghai Changzheng Hospital, with a status the registry has not verified recently.
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 is a phase 2 interventional study registered as NCT03329183 by Shanghai Changzheng Hospital, with 90 participants planned, started 2019-03 and due to reach its primary completion in 2019-03. Interventions recorded: Irinotecan. Conditions recorded: Colorectal Cancer.
Linked to the technology UGT1A1 genotyping before irinotecan because the registry's title names it ("ugt1a1 6") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan) and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.